Cat. No.: HY-10238

Danoprevir

(Synonyms: ITMN-191; R7227; RO5190591; RG7227)

20 Cited Publications

Customer Review

Based on 20 publication(s) in Google Scholar

Danoprevir (ITMN-191) is an orally active NS3/4A protease inhibitor for hepatitis C virus (HCV) with an IC₅₀ of 0.29 nM and is selective for NS3/4A over a panel of 53 proteases (IC₅₀ higher than 10 μM). Danoprevir (ITMN-191) inhibits HCV genotypes 1a, 1b, 4, 5, and 6 (IC₅₀s=0.2-0.4 nM) as well as 2b and 3a (IC₅₀s=1.6, 3.5 nM). Danoprevir is also a SARS-CoV 3CL^pro inhibitor with an IC₅₀ of 0.05 μM.

For research use only. We do not sell to patients.

Purity: 99.67%
CAS No.: 850876-88-9
Formula: C₃₅H₄₆FN₅O₉S
Molecular Weight:731.83

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Danoprevir Chemical Structure

CAS No.: 850876-88-9

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (20)
Solvent & Solubility
- In Vitro
- In Vivo
Protocol
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

Danoprevir (ITMN-191) is an orally active NS3/4A protease inhibitor for hepatitis C virus (HCV) with an IC₅₀ of 0.29 nM and is selective for NS3/4A over a panel of 53 proteases (IC₅₀ higher than 10 μM). Danoprevir (ITMN-191) inhibits HCV genotypes 1a, 1b, 4, 5, and 6 (IC₅₀s=0.2-0.4 nM) as well as 2b and 3a (IC₅₀s=1.6, 3.5 nM)^[1]^[2]. Danoprevir is also a SARS-CoV 3CL^pro inhibitor with an IC₅₀ of 0.05 μM^[3].

IC₅₀ & Target

IC50: 0.29 nM (NS3/4A protease), 0.2-3.5 nM (HCV genotypes 1a, 1b, 2b, 3a, 4, 5, 6)^[2]

Cellular Effect

Cell Line	Type	Value	Description	References
Huh-7	EC₅₀	<0.25 nM Compound: 49, Danoprevir, ITMN-191, R7227	Antiviral activity against Hepatitis C virus harboring wild type NS3/4A protease infected in human HuH7 cells assessed as inhibition of HCV subgenomic replicon replication after 72 hrs by ELISA Antiviral activity against Hepatitis C virus harboring wild type NS3/4A protease infected in human HuH7 cells assessed as inhibition of HCV subgenomic replicon replication after 72 hrs by ELISA	[PMID: 23672640]
Huh-7	EC₅₀	0.011 μM Compound: 5	Antiviral activity against HCV infected in human HuH7 cells by cell based replicon assay Antiviral activity against HCV infected in human HuH7 cells by cell based replicon assay	[PMID: 27160057]
Huh-7	EC₅₀	0.25 nM Compound: ITMN-191	Antiviral activity against HCV1b harboring Q80Q polymorphism in NS3 protease gene infected in human Huh7/Lunet cells assessed as inhibition of viral replication after 3 days by luciferase based transient-transfection assay Antiviral activity against HCV1b harboring Q80Q polymorphism in NS3 protease gene infected in human Huh7/Lunet cells assessed as inhibition of viral replication after 3 days by luciferase based transient-transfection assay	[PMID: 20855726]
Huh-7	EC₅₀	0.5 nM Compound: 49, Danoprevir, ITMN-191, R7227	Antiviral activity against Hepatitis C virus harboring NS3/4A protease A156T mutant gene infected in human HuH7 cells assessed as inhibition of HCV subgenomic replicon replication after 72 hrs by ELISA Antiviral activity against Hepatitis C virus harboring NS3/4A protease A156T mutant gene infected in human HuH7 cells assessed as inhibition of HCV subgenomic replicon replication after 72 hrs by ELISA	[PMID: 23672640]
Huh-7	EC₅₀	0.6 nM Compound: ITMN-191	Antiviral activity against HCV1b Con1 harboring NS3 protease gene infected in human Huh7/Lunet cells assessed as inhibition of viral replication after 3 days by luciferase based transient-transfection assay Antiviral activity against HCV1b Con1 harboring NS3 protease gene infected in human Huh7/Lunet cells assessed as inhibition of viral replication after 3 days by luciferase based transient-transfection assay	[PMID: 20855726]
Huh-7	EC₅₀	0.62 nM Compound: ITMN-191	Antiviral activity against HCV1b harboring Q80K polymorphism in NS3 protease gene infected in human Huh7/Lunet cells assessed as inhibition of viral replication after 3 days by luciferase based transient-transfection assay Antiviral activity against HCV1b harboring Q80K polymorphism in NS3 protease gene infected in human Huh7/Lunet cells assessed as inhibition of viral replication after 3 days by luciferase based transient-transfection assay	[PMID: 20855726]
Huh-7	EC₅₀	1 nM Compound: ITMN191	Antiviral activity against HCV 1a infected in human Huh-7 cells after 48hrs by luciferase assay Antiviral activity against HCV 1a infected in human Huh-7 cells after 48hrs by luciferase assay	[PMID: 21067923]
Huh-7	EC₅₀	1.1 nM Compound: ITMN191	Antiviral activity against HCV 1b infected in human Huh-7 cells after 48hrs by luciferase assay Antiviral activity against HCV 1b infected in human Huh-7 cells after 48hrs by luciferase assay	[PMID: 21067923]
Huh-7	EC₅₀	1.6 nM Compound: 49, Danoprevir, ITMN-191, R7227	Antiviral activity against Hepatitis C virus genotype 1b infected in human HuH7 cells assessed as decrease in replicon RNA level after 2 days by TaqMan Gold RT-PCR analysis Antiviral activity against Hepatitis C virus genotype 1b infected in human HuH7 cells assessed as decrease in replicon RNA level after 2 days by TaqMan Gold RT-PCR analysis	[PMID: 23672640]
Huh-7	EC₅₀	2.1 nM Compound: RG-7227, ITMN-191	Antiviral activity against HCV 1B infected in human Huh7 cells by firefly luciferase reporter gene assay Antiviral activity against HCV 1B infected in human Huh7 cells by firefly luciferase reporter gene assay	[PMID: 20541424]
Huh-7	EC₅₀	2.4 nM Compound: 49, Danoprevir, ITMN-191, R7227	Antiviral activity against Hepatitis C virus infected in human HuH7 cells assessed as inhibition of HCV subgenomic replicon replication after 72 hrs by ELISA Antiviral activity against Hepatitis C virus infected in human HuH7 cells assessed as inhibition of HCV subgenomic replicon replication after 72 hrs by ELISA	[PMID: 23672640]
Huh-7	EC₅₀	20 nM Compound: 49, Danoprevir, ITMN-191, R7227	Antiviral activity against Hepatitis C virus genotype 2 infected in human HuH7 cells assessed as decrease in replicon RNA level after 2 days by TaqMan Gold RT-PCR analysis Antiviral activity against Hepatitis C virus genotype 2 infected in human HuH7 cells assessed as decrease in replicon RNA level after 2 days by TaqMan Gold RT-PCR analysis	[PMID: 23672640]
Huh-7	EC₅₀	20 nM Compound: 49, Danoprevir, ITMN-191, R7227	Antiviral activity against Hepatitis C virus genotype 3 infected in human HuH7 cells assessed as decrease in replicon RNA level after 2 days by TaqMan Gold RT-PCR analysis Antiviral activity against Hepatitis C virus genotype 3 infected in human HuH7 cells assessed as decrease in replicon RNA level after 2 days by TaqMan Gold RT-PCR analysis	[PMID: 23672640]
Huh-7	IC₅₀	0.24 nM Compound: 49, Danoprevir, ITMN-191, R7227	Antiviral activity against Hepatitis C virus genotype 1a isolate Con1 harboring wild type NS3/4A protease infected in human HuH7 cells assessed as inhibition of HCV replicon replication by luciferase assay Antiviral activity against Hepatitis C virus genotype 1a isolate Con1 harboring wild type NS3/4A protease infected in human HuH7 cells assessed as inhibition of HCV replicon replication by luciferase assay	[PMID: 23672640]
Huh-7	IC₅₀	5.7 nM Compound: 49, Danoprevir, ITMN-191, R7227	Antiviral activity against Hepatitis C virus genotype 1a isolate Con1 harboring NS3/4A protease A156T mutant gene infected in human HuH7 cells assessed as inhibition of HCV replicon replication by luciferase assay Antiviral activity against Hepatitis C virus genotype 1a isolate Con1 harboring NS3/4A protease A156T mutant gene infected in human HuH7 cells assessed as inhibition of HCV replicon replication by luciferase assay	[PMID: 23672640]

In Vitro

In Huh7.5 cells transfected with chimeric recombinant virus, Danoprevir (ITMN-191) shows antiviral inhibition effects against HCV genotypes 1, 4 and 6 with IC₅₀ of 2-3 nM, which are >100-fold lower than genotypes 2/3/5 (280-750 nM)^[1].
Danoprevir (ITMN-191) inhibits the reference genotype 1 NS3/4A protease half-maximally, but a high dose of Danoprevir (ITMN-191) (10 μM) shows no appreciably inhibition in a panel of 79 proteases, ion channels, transporters, and cell surface receptors. Danoprevir (ITMN-191) remains bound to and inhibits NS3/4A for more than 5 hours after its initial association. Danoprevir (ITMN-191) (45 nM) eliminates a patient-derived HCV genotype 1b replicon from hepatocyte-derived Huh7 cells with an EC₅₀ of 1.8 nM^[2].
In HCV subgenomic replicon cell lines containing the individual mutations, V36M, R109K, and V170A substitutions confer little or no resistance to Danoprevir (ITMN-191), but the R155K substitution confers a high level (62-fold increase) of resistance to Danoprevir^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Danoprevir (ITMN-191) (30 mg/kg, p.o.) administered to rats or monkeys shows that its concentrations in liver 12 hours after dosing exceed the Danoprevir concentration required to eliminate replicon RNA from cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 850876-88-9
Appearance Solid
Molecular Weight 731.83
Formula C₃₅H₄₆FN₅O₉S
Color White to off-white
SMILES

O=S(NC([C@@]1(NC([C@]2([H])C[C@@H](OC(N3CC4=C(C3)C=CC=C4F)=O)CN2C5=O)=O)C[C@]1(/C=C/CCCCC[C@@H]5NC(OC(C)(C)C)=O)[H])=O)(C6CC6)=O
Synonyms

ITMN-191; R7227; RO5190591; RG7227
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (20)

All WB

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. [Abstract]

2021 May 29;6(1):212. PMID: 34052830
Nat Methods

Chemogenetic control of gene expression and cell signaling with antiviral drugs. [Abstract]

2018 Jul;15(7):519-522. PMID: 29967495
Cell Res

Engineered poly(A)-surrogates for translational regulation and therapeutic biocomputation in mammalian cells. [Abstract]

2024 Jan;34(1):31-46. PMID: 38172533
Nat Commun

A system for the continuous directed evolution of proteases rapidly reveals drug-resistance mutations. [Abstract]

2014 Oct 30;5:5352. PMID: 25355134
Int J Radiat Oncol Biol Phys

Targeting Phosphatidylinositol 4-Kinase IIIα for Radiosensitization: A Potential Model of Drug Repositioning Using an Anti-Hepatitis C Viral Agent. [Abstract]

2016 Nov 15;96(4):867-876. PMID: 27788957
Fungal Biol

The serine peptidase inhibitor N-ρ-tosyl-l-phenylalanine chloromethyl ketone (TPCK) affects the cell biology of Candida haemulonii species complex. [Abstract]

2021 May;125(5):378-388. PMID: 33910679
Virology

Human pegivirus (GB virus C) NS3 protease activity inhibits induction of the type I interferon response and is not inhibited by HCV NS3 protease inhibitors. [Abstract]

2014 May;456-457:300-9. PMID: 24889249

Danoprevir purchased from MedChemExpress. Usage Cited in: Virology. 2014 May;456-457:300-9. [Abstract]

Jurkat cells are transfected with plasmids expressing (A) HCV NS3/4A or (B) HPgV NS3/4AB-HA. Telaprevir, Boceprevir, and Danoprevir are added at concentrations of 100 µM, 16.6 µM, 2.7 µM, or 0 µM in 0.1% DMSO. Lysates are harvested after 24 h and resolved by immunoblots probed with anti-HCV NS3 (A) or anti-HA (B). The position of HCV NS3/4A (~75kDa), HCV NS3 (~73kDa), NS3/4AB-HA, and NS4B-HA (~30kDa) are indicated. Molecular markers are on the right.
Avicenna J Phytomed

Inhibitory activity of limonoids from Khaya grandifoliola C.DC (Meliaceae) against hepatitis C virus infection in vitro. [Abstract]

2021 Jul-Aug;11(4):353-366. PMID: 34290967
Boston University

2025.
bioRxiv

Replating induces mTOR-dependent rescue of protein synthesis in Charcot-Marie-Tooth diseased neurons. [Abstract]

2025 Aug 31:2025.08.26.672367. PMID: 40909707
Patent

US12065501.
University of Colorado Denver

2024.
bioRxiv

Orthogonal inducible control of Cas13 circuits enables programmable RNA regulation in mammalian cells. [Abstract]

2023 Mar 20:2023.03.20.533499. PMID: 36993327
bioRxiv

Controlled protein activities with viral proteases, antiviral peptides, and antiviral drugs. [Abstract]

2023 Feb 27:2023.02.27.530290. PMID: 36909459
Patent

US20210238569A1.
bioRxiv

2020 Apr.
Patent

US20190010245A1.
Patent

US20180346589A1.
Patent

US20170233708A1.
Seoul National University

2016 Aug.

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL (136.64 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.3664 mL

6.8322 mL

13.6644 mL

5 mM

0.2733 mL

1.3664 mL

2.7329 mL

10 mM

0.1366 mL

0.6832 mL

1.3664 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (3.42 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (3.42 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocol

Kinase Assay^[2]

The assay buffer contains 25 μM NS4A peptide, 50 mM Tris-HCl, pH 7.5, 15% (vol/vol) glycerol, 0.6 mM lauryldimethylamine N-oxide, 10 mM dithiothreitol, and 0.5 μM fluorescein/QXL520-labeled FRET substrate {Ac-DE-Dap(QXL520)-EE-Abu-ψ-[COO]-AS-Cys(5-FAMsp)-NH2}. K2040 enzyme (50 pM) is added to initiate the reaction. Reactions are set up in black 96-well plates, and fluorescence data is collected. Control reactions lacking inhibitors and enzyme are included. Initial rates are calculated from the linear phase of the reaction (up to 1 hour) and are used to obtain IC₅₀. Recovery of activity from preformed Danoprevir-NS3/4A complex is assessed by preincubating 10 nM NS3/4A with a two-fold excess of Danoprevir in 1× assay buffer for 15 min, followed by a rapid 200-fold dilution of the preformed complex into assay buffer containing substrate. A control reaction with the same final conditions without preincubation of NS3/4A and Danoprevir is initiated by the addition of enzyme to an otherwise-complete reaction mixture. Additional control reactions lack either Danoprevir or NS3. The progress of the reactions is followed over 5 hours.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[2]

Pharmacokinetic properties are evaluated in rats and monkeys. Sprague-Dawley rats (three per time point) are administered a 30-mg/kg of body weight dose of ITMN-191 by oral gavage (a 6-mg/mL solution in water). Cynomolgus monkeys (two per time point) are administered a 30-mg/kg dose of ITMN-191 by oral gavage (a 3-mg/mL solution in water). For each species, terminal blood samples and the entire perfused liver are collected 1, 4, 8, 12, and 24 h after dose administration. Blood samples are collected in EDTA, processed for plasma by centrifugation at 5°C, and stored at −20°C until analysis is performed. Liver samples are snap-frozen and stored at −70°C until analysis is performed. Blank, standard, and unknown plasma samples and homogenized liver containing an internal standard (ITMN-191 analog) are treated with acidified acetonitrile and centrifuged to remove precipitated proteins. The density of liver tissue is taken into account to allow concentrations in both compartments to be expressed as weight per unit volume. The cleared supernatants are diluted 1:1 into high-performance liquid chromatography grade water and analyzed on a 4000 Q-trap liquid chromatography-tandem mass spectrometer fitted with the Turbo-Ionspray source operating in negative-ion mode. Analytes and internal standards are monitored using multiple-reaction-monitoring scans and calibrated with ABI Analyst software, version 1.4.2. The calibration standards ranges from 0.0169 ng/mL to 37.0 ng/mL and from 7.47 ng/mL to 5,440 ng/mL for the quantification of plasma samples and liver homogenates, respectively. Quadratic fitting with 1/x weighting is utilized where an R2 value of > 0.999 is achieved in both matrices.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (290 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Imhof I, et al. Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191).Hepatology. 2011 Apr;53(4):1090-9. [Content Brief]

[2]. Seiwert, Scott D., et al. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227). Antimicrobial Agents and Chemotherapy (2008), 52(12), 4432-4441.

[3]. Bartels DJ, et al. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J Infect Dis. 2008 Sep 15;198(6):800-7. [Content Brief]

[4]. Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6(1):212. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.3664 mL	6.8322 mL	13.6644 mL	34.1609 mL
	5 mM	0.2733 mL	1.3664 mL	2.7329 mL	6.8322 mL
	10 mM	0.1366 mL	0.6832 mL	1.3664 mL	3.4161 mL
	15 mM	0.0911 mL	0.4555 mL	0.9110 mL	2.2774 mL
	20 mM	0.0683 mL	0.3416 mL	0.6832 mL	1.7080 mL
	25 mM	0.0547 mL	0.2733 mL	0.5466 mL	1.3664 mL
	30 mM	0.0455 mL	0.2277 mL	0.4555 mL	1.1387 mL
	40 mM	0.0342 mL	0.1708 mL	0.3416 mL	0.8540 mL
	50 mM	0.0273 mL	0.1366 mL	0.2733 mL	0.6832 mL
	60 mM	0.0228 mL	0.1139 mL	0.2277 mL	0.5693 mL
	80 mM	0.0171 mL	0.0854 mL	0.1708 mL	0.4270 mL
	100 mM	0.0137 mL	0.0683 mL	0.1366 mL	0.3416 mL

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Danoprevir

Anti-Infection Compound Library

Metabolism/Protease Compound Library

FDA-Approved Drug Library

Antiviral Compound Library

Drug Repurposing Compound Library

Macrocyclic Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Hepatitis C Virus Compound Library

Heterocyclic Compound Library

Off-patent Drug Library

Protease Inhibitor Library

Highly Selective Inhibitors Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Danoprevir

Biological Activity

Chemical Information

Publications (20)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Danoprevir

Anti-Infection Compound Library

Metabolism/Protease Compound Library

FDA-Approved Drug Library

Antiviral Compound Library

Drug Repurposing Compound Library

Macrocyclic Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Hepatitis C Virus Compound Library

Heterocyclic Compound Library

Off-patent Drug Library

Protease Inhibitor Library

Highly Selective Inhibitors Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Danoprevir

Biological Activity

Chemical Information

Publications (20)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Danoprevir Related Classifications

Cat. No.: HY-10238